Publications: DR Francesca Jackson-Spence

Powles T, Hussain SA, Climent MA, Carbonero IG, Molina-Cerrillo J, Puente J, Borrega P, Malik J et al. ( 2025 ) . Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial ☆ . Annals of Oncology vol. 37 , ( 2 ) 250 - 259 .

Wells JC, Membribes SC, Nally E, Jackson-Spence F, Lalwani SB, Graham C, Szabados BE, Powles TB ( 2025 ) . 3130eP Time commitment requirements for clinical trial participation in patients with metastatic urothelial carcinoma . Annals of Oncology vol. 36 ,

Jackson-Spence F, Loriot Y, Ackerman C, García-Carbonero I, Hussain SA, Walker G, Sarwar N, Barrera RM et al. ( 2025 ) . 3132eP The feasibility of wearable devices to assess patient reported outcomes in urothelial cancer trials: The DISCUS substudy . Annals of Oncology . vol. 36 ,

Pulido EG, Hussain SA, Duran MAC, Jackson-Spence F, García-Carbonero I, Cerrillo JM, Puente J, Borrega P et al. ( 2025 ) . LBA109 DISCUS: A phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer . Annals of Oncology . vol. 36 ,

Membribes SC, Nally E, Jackson-Spence F, Graham C, Lalwani S, Szabados B, Powles T ( 2025 ) . Established and emerging biomarkers approaches in urothelial carcinoma . Expert Review of Anticancer Therapy vol. 25 , ( 11 ) 1235 - 1241 .

Jackson-Spence F, Larkin J, Patel P, Valderrama BP, Rodriguez-Vida A, Mendez-Vidal MJ, Childress M, Li W et al. ( 2025 ) . Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO) . Journal of Clinical Oncology vol. 43 , ( 5_suppl ) 444 - 444 .

Nally E, Ainsworth G, Brown SR, Bergerot CD, Wells C, Young MN, Westerman T, Coca S et al. ( 2025 ) . Improving health related quality of life (HRQoL) assessment and immune related adverse event (irAE) classification with novel tools in renal cancer . Journal of Clinical Oncology vol. 43 , ( 5_suppl ) 525 - 525 .

Wells C, Nally E, Jackson-Spence F, Coca S ( 2025 ) . Systemic therapy clinical trial participation in patients with bladder and kidney cancers . Journal of Clinical Oncology vol. 43 , ( 5_suppl ) 451 - 451 .

Bickley LJ, Yang Y-H, Jackson-Spence F, Toms C, Sng C, Flanders L, Bex A, Powles T et al. ( 2024 ) . Systemic therapies and primary tumour downsizing in renal cell carcinoma: a real-world comparison of anti-angiogenic and immune checkpoint inhibition regimens . World Journal of Urology vol. 42 , ( 1 )

Young M, Jackson-Spence F, Beltran L, Day E, Suarez C, Bex A, Powles T, Szabados B ( 2024 ) . Renal cell carcinoma . The Lancet vol. 404 , ( Diagn Pathol 10 2015 ) 476 - 491 .

Jackson-Spence F, Ackerman C, Jones R, Toms C, Jovaisaite A, Young M, Hussain S, Protheroe A et al. ( 2024 ) . Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel . Urologic Oncology Seminars and Original Investigations vol. 42 , ( 11 ) 372.e1 - 372.e10 .

Nally E, Young M, Wells C, Fairhead R, Baines K, Cheney-Lowe H, Jackson-Spence F, Powles T ( 2024 ) . Is HER2 the New NECTIN4 in Advanced Urothelial Cancer? . European Urology Focus vol. 10 , ( 2 ) 219 - 221 .

Chauhan V, Diaz SS, Jara P, Efovi D, Gurung A, Young M, Wells C, Nally E et al. ( 2024 ) . Abstract B013: Novel prognostic score for patients with metastatic bladder cancer on immunotherapy . Clinical Cancer Research vol. 30 , ( 10_Supplement ) b013 - b013 .

Nally E, Young M, Chauhan V, Wells C, Szabados B, Powles T, Jackson-Spence F ( 2024 ) . Upper Tract Urothelial Carcinoma (UTUC): Prevalence, Impact and Management Challenge . Cancer Management and Research vol. 16 , ( 0 ) 467 - 475 .

Young M, Tapia JC, Szabados B, Jovaisaite A, Jackson-Spence F, Nally E, Powles T ( 2024 ) . NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors . Clinical Genitourinary Cancer vol. 22 , ( 3 )

Diaz SS, Chauhan V, Gurung A, Nally E, Young M, Wells C, Jackson-Spence F, Szabados B et al. ( 2024 ) . A0745 Analysing resistance and progression patterns to immune checkpoint inhibitors in urothelial carcinoma . European Urology vol. 85 ,

Jackson-Spence F, Chauhan V, Silva Diaz S, Gurung A, Young MN, Nally E, Wells C, Szabados B et al. ( 2024 ) . Identification of patients with metastatic urothelial cancer not able to receive maintenance avelumab . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 702 - 702 .

Young MN, Szabados B, Assaf Z, Jackson-Spence F, Nally E, Wells C, Suárez C, Castellano D et al. ( 2024 ) . Predictive value of dynamic changes in ctDNA and baseline biomarkers with neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 534 - 534 .

Jackson-Spence F, Young M, Jovaisaite A, Szabados B, Powles T ( 2024 ) . Adjuvant Therapy in Renal Cell Cancer . Kidney Cancer vol. 8 , ( 1 ) 17 - 22 .

Jackson-Spence F, Rodriguez CS, Larkin J, Patel P, Valderrama BP, Rodriguez-Vida A, Vidal MJM, Markovets A et al. ( 2023 ) . 1888P 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer . Annals of Oncology . vol. 34 ,

Yang Y-H, Cubuk C, Gauna DEC, Banchereau R, Kockx M, Rodriguez-Vida A, Martinez ID, Crabb S et al. ( 2023 ) . 2393P Ephrin signalling mediates resistance to programmed death ligand 1 (PD-L1) inhibition in urothelial carcinoma (UC) . Annals of Oncology vol. 34 ,

Jackson-Spence F, Marin AP, Puente J, Molina-Cerrillo J, Hussain SA, Ackerman C, Kelly J, Powles TB ( 2023 ) . 2408TiP DISCUS: A randomised phase II study of 3 vs 6 cycles of chemotherapy followed by maintenance avelumab in advanced urothelial cancer - Wearable devices and circulating biomarkers assessing quality of life and surrogate efficacy endpoints . Annals of Oncology vol. 34 , s1224 - s1225 .

Jackson‐Spence F, Young M, Sweeney C, Powles T ( 2023 ) . Top advances of the year: Genitourinary cancer . Cancer vol. 129 , ( 17 ) 2603 - 2609 .

Jovaisaite A, Serrano M, Jackson-Spence F, Young M, Toms C, Wang Y, Nally E, Szabados B et al. ( 2023 ) . Immune-related adverse events after ≥12 months of starting immune checkpoint inhibitors . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) e24086 - e24086 .

Tapia JC, Toms C, Wang Y, Jovaisaite A, Young MN, Jackson-Spence F, Powles T, Szabados B ( 2023 ) . Outcomes and safety of subsequent treatments after immune- and anti-VEGF therapy in patients with metastatic clear-cell renal cell carcinoma: Outcomes from a tertiary referral hospital . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) e16533 - e16533 .

Jackson-Spence F, Toms C, O'Mahony LF, Choy J, Flanders L, Szabados B, Powles T ( 2023 ) . IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery . Future Oncology vol. 19 , ( 7 ) 509 - 515 .

Jackson-Spence F, Ackerman C, Szabados B, Toms C, Jovaisaite A, Gunnell R, Suárez C, Larkin J et al. ( 2023 ) . DNA alterations in papillary renal cancer . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) 725 - 725 .

Yang Y-H, Ansel S, Meerveld-Eggink A, Jackson-Spence F, Rallis K, Brian P, Choy J, Sng C et al. ( 2023 ) . Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study . Clinical Genitourinary Cancer vol. 21 , ( 4 ) e242 - e251 .

Jovaisaite A, Serrano M, Jackson-Spence F, Young M, Toms C, Wang Y, Nally E, Szabados B et al. ( 2023 ) . Immune-related adverse events after ≥12 months of starting immune checkpoint inhibitors . JOURNAL OF CLINICAL ONCOLOGY . vol. 41 ,

Tapia JC, Toms C, Wang Y, Jovaisaite A, Young MN, Jackson-Spence F, Powles T, Szabados B ( 2023 ) . Outcomes and safety of subsequent treatments after immune- and anti-VEGF therapy in patients with metastatic clear-cell renal cell carcinoma: Outcomes from a tertiary referral hospital . JOURNAL OF CLINICAL ONCOLOGY . vol. 41 ,

Jackson-Spence FE, Powles T, Loriot Y, Toms C, Jovaisaite A, Choy J, Szabados BE, Nudds H et al. ( 2022 ) . P126 Trial In Progress: DISCUS: A randomized phase II study comparing 3 vs. 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer . European Urology Open Science vol. 45 ,

Jackson-Spence FE, O’Mahony LF, Toms C, Flanders L, Hockings H, Choy J, Szabados BE, Powles T ( 2022 ) . P159 Outcomes of patients with metastatic urothelial cancer who have received previous first line therapy . European Urology Open Science vol. 45 ,

Loo Gan C, Huang J, Pan E, Xie W, Schmidt AL, Labaki C, Meza L, Bouchard G et al. ( 2022 ) . Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium . European Urology Oncology vol. 6 , ( 2 ) 204 - 211 .

Jurascheck L, Yang Y-H, Jackson-Spence F, Toms C, Sng CC, Flanders L, Powles TB, Szabados BE ( 2022 ) . 1467P Optimal neoadjuvant treatment choice for localised renal cell carcinoma . Annals of Oncology vol. 33 ,

O'Mahony LFF, Jackson-Spence F, Toms C, Flanders L, Hockings HA, Choy J, Powles TB, Szabados BE ( 2022 ) . 1767P Outcomes after first line therapy in metastatic bladder and upper tract cancer . Annals of Oncology vol. 33 ,

Jackson-Spence FE, Toms C, Yang Y-H, Walshaw L, Caldwell L, Riddell A, Cutino-Moguel M-T, Szabados B et al. ( 2022 ) . A0389 The effect of anti-cancer therapy on immunological response to COVID-19 vaccination . European Urology vol. 81 ,

Szabados B, Duncan S, Choy J, Jackson-Spence F, Toms C, Trevisan G, Berney DM, Powles T et al. ( 2022 ) . Androgen Receptor Expression Is a Predictor of Poor Outcome in Urothelial Carcinoma . Frontiers in Urology vol. 2 ,

Yang Y-H, Meerveld-Eggink A, Bex A, Jackson-Spence F, Rallis KS, Brian PR, Choy J, Sng CC et al. ( 2022 ) . 18P Baseline and dynamic changes in haemoglobin levels predict treatment response and disease progression in metastatic renal cell carcinoma . Annals of Oncology vol. 33 ,

Jackson-Spence F, Toms C, Yang Y-H, Walshaw L, Riddell A, Cutino-Moguel M-T, Szabados B, Propper D et al. ( 2022 ) . The effect of anti-cancer therapy on immunological response to COVID-19 vaccination . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 319 - 319 .

Jackson-Spence F, Szabados B, Toms C, Yang Y-H, Sng C, Powles T ( 2022 ) . Avelumab in locally advanced or metastatic urothelial carcinoma . Expert Review of Anticancer Therapy vol. 22 , ( 2 ) 135 - 140 .

Jackson-Spence F, Toms C, Yang Y-H, Jurascheck L, Choy J, Flanders L, Szabados B, Powles T ( 2022 ) . The role of modern immunotherapy in metastatic urothelial cancer: mini review . Journal of Cancer Metastasis and Treatment vol. 8 , ( 0 ) null - null .

Butters T, Liu WK, Grant M, Jackson-Spence F, Zaynub G, So A, Lam J, Ashfar M et al. ( 2021 ) . What do Emergency Physicians Know About Immune Checkpoint Inhibitor-Related Toxicities: A Brief Report . International Journal of Cancer Management vol. 14 , ( 8 )

Jackson-Spence FE, Ackerman C, Khan M, Grant M, Soosaipillai G, Nally E, Choy J, Powles TB et al. ( 2021 ) . P0461 The role of angiogenic signatures in advanced urothelial carcinoma (aUC) treated with VEGF-targeted therapy . European Urology vol. 79 ,

Khan MA, Szabados B, Choy J, Jackson-Spence F, Powles T, Castellano D, Valderrama BP ( 2021 ) . Patient outcomes following disease progression with enfortumab-vedotin (EV) in metastatic urothelial carcinoma (mUC) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) e16516 - e16516 .

Szabados B, Prendergast A, Jackson-Spence F, Choy J ( 2021 ) . Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer . European Urology Oncology vol. 4 , ( 6 ) 943 - 947 .

Abu Ghanem Y, Choy J, Jackson-Spence F, Jovaisaite A, Grant M, Bex A, Powles T, Szabados B ( 2020 ) . Dynamic changes in full blood count (FBC) occurring in patients treated with immune checkpoint inhibitors (ICIs) to predict responses in patients with metastatic renal cell carcinoma (mRCC) . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) e17110 - e17110 .

Liu WK, Lam JM, Butters T, Grant M, Bex A, Powles T ( 2020 ) . Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach . World Journal of Urology vol. 38 , ( 12 ) 3199 - 3205 .

Jackson-Spence F, Jovaisaite A, Grant M, Liu W-K, Butters T, Powles T, Szabados B ( 2020 ) . Outcomes after first-line therapy for immune/immune or immune/VEGF combinations . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 706 - 706 .

Abu Ghanem Y, Choy J, Jackson-Spence F, Jovaisaite A, Grant M, Bex A, Powles T, Szabados B ( 2020 ) . Dynamic changes in full blood count (FBC) occurring in patients treated with immune checkpoint inhibitors (ICIs) to predict responses in patients with metastatic renal cell carcinoma (mRCC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Jackson-Spence F, Jovaisaite A, Grant M, Liu W-K, Butters T, Powles T, Szabados B ( 2020 ) . Outcomes after first-line therapy for immune/immune or immune/VEGF combinations . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Arshad A, Jackson‐Spence F, Sharif A ( 2019 ) . Development and evaluation of dedicated low clearance transplant clinics for patients with failing kidney transplants . Journal of Renal Care vol. 45 , ( 1 ) 51 - 58 .

Jackson‐Spence F, Gillott H, Tahir S, Nath J, Mytton J, Evison F, Sharif A ( 2018 ) . Mortality risk after cancer diagnosis in kidney transplant recipients: the limitations of analyzing hospital administration data alone . Cancer Medicine vol. 7 , ( 3 ) 931 - 939 .

Johal S, Jackson‐Spence F, Gillott H, Tahir S, Mytton J, Evison F, Stephenson B, Nath J et al. ( 2017 ) . Pre‐existing diabetes is a risk factor for increased rates of cellular rejection after kidney transplantation: an observational cohort study . Diabetic Medicine vol. 34 , ( 8 ) 1067 - 1073 .

Tahir S, Gillott H, Jackson-Spence F, Nath J, Mytton J, Evison F, Sharif A ( 2017 ) . Do outcomes after kidney transplantation differ for black patients in England versus New York State? A comparative, population-cohort analysis . BMJ Open vol. 7 , ( 5 )

Jackson-Spence F, Gillott H, Tahir S, Nath J, Mytton J, Evison F, Sharif A ( 2017 ) . Balancing risks for older kidney transplant recipients in the contemporary era: A single-centre observational study . European Geriatric Medicine vol. 8 , ( 1 ) 42 - 47 .

Jackson‐Spence F, Gillott H, Tahir S, Nath J, Mytton J, Evison F, Sharif A ( 2017 ) . Cancer‐related outcomes in kidney allograft recipients in England versus New York State: a comparative population‐cohort analysis between 2003 and 2013 . Cancer Medicine vol. 6 , ( 3 ) 563 - 571 .

Gillott H, Jackson-Spence F, Tahir S, Evison F, Nath J, Sharif A ( 2016 ) . MP696SMOKING EXPOSURE AMONG KIDNEY ALLOGRAFT RECIPIENTS AND OUTCOMES AFTER TRANSPLANT . Nephrology Dialysis Transplantation vol. 31 , ( suppl_1 ) i571 - i571 .

Abbas S, Tahir S, Gillott H, Jackson-Spence F, Mytton J, Evison F, Nath J, Ferro CJ et al. ( 2016 ) . MP728SOCIOECONOMIC DEPRIVATION AND OUTCOMES AFTER KIDNEY TRANSPLANTATION . Nephrology Dialysis Transplantation vol. 31 , ( suppl_1 ) i581 - i581 .

Jackson-Spence F, Gillott H, Tahir S, Nath J, Evison F, Sharif A ( 2016 ) . MP741AGE ADAPTED IMMUNOSUPPRESSION FOR ELDERLY KIDNEY ALLOGRAFT RECIPIENTS: BALANCING RISKS FOR CANCER VERSUS REJECTION . Nephrology Dialysis Transplantation vol. 31 , ( suppl_1 ) i585 - i585 .

Jackson-Spence F, Gillott H, Tahir S, Nath J, Mytton J, Evison F, Sharif A ( 2016 ) . SP642CANCER INCIDENCE AND PROGRESSION TO MORTALITY AMONG KIDNEY ALLOGRAFT RECIPIENTS IN ENGLAND: A POPULATION-COHORT ANALYSIS BETWEEN 2003 AND 2013 . Nephrology Dialysis Transplantation vol. 31 , ( suppl_1 ) i310 - i310 .

Jackson-Spence F, Gillott H, Tahir S, Nath J, Mytton J, Evison F, Sharif A ( 2016 ) . SP662CANCER-RELATED OUTCOMES IN KIDNEY ALLOGRAFT RECIPIENTS IN ENGLAND VERSUS NEW YORK STATE: A COMPARATIVE POPULATION-COHORT ANALYSIS BETWEEN 2003 AND 2013 . Nephrology Dialysis Transplantation vol. 31 , ( suppl_1 ) i315 - i316 .

Tahir S, Gillott H, Jackson-Spence F, Evison F, Nath J, Sharif A ( 2016 ) . SP679OUTCOMES FOR KIDNEY ALLOGRAFT RECIPIENTS WITH LANGUAGE BARRIERS POST-TRANSPLANTATION - A COMPARATIVE ANALYSIS . Nephrology Dialysis Transplantation vol. 31 , ( suppl_1 ) i321 - i321 .

Gillott H, Tahir S, Jackson-Spence F, Evison F, Nath J, Sharif A ( 2016 ) . SP685DONOR SMOKING INCREASES KIDNEY ALLOGRAFT RECIPIENT MORTALITY IN A NATIONAL POPULATION COHORT ANALYSIS . Nephrology Dialysis Transplantation vol. 31 , ( suppl_1 ) i323 - i323 .

Tahir S, Gillott H, Jackson-Spence F, Nath J, Mytton J, Evison F, Sharif A ( 2016 ) . SP686BLACK KIDNEY ALLOGRAFT RECIPIENT OUTCOMES IN ENGLAND VS NEW YORK STATE: A COMPARATIVE POPULATION-COHORT ANALYSIS BETWEEN 2003 AND 2013 . Nephrology Dialysis Transplantation vol. 31 , ( suppl_1 ) i323 - i323 .

Jackson-Spence F, Gillott H, Tahir S, Nath J, Evison F, Sharif A ( 2016 ) . AGE ADAPTED IMMUNOSUPPRESSION FOR ELDERLY KIDNEY ALLOGRAFT RECIPIENTS: BALANCING RISKS FOR CANCER VERSUS REJECTION . NEPHROLOGY DIALYSIS TRANSPLANTATION . vol. 31 , 1585 - 1585 .

Jackson-Spence F, Gillott H, Tahir S, Evison F, Nath J, Sharif A ( 2016 ) . Age Adapted Immunosuppression for Elderly Kidney Allograft Recipients: Balancing Risks for Cancer versus Rejection . AMERICAN JOURNAL OF TRANSPLANTATION . vol. 16 , 687 - 687 .

Jackson-Spence F, Gillott H, Tahir S, Nath J, Evison F, Sharif A ( 2016 ) . Age adapted immunosuppression for elderly kidney allograft recipients: balancing risks for cancer versus rejection . TRANSPLANTATION . vol. 100 , S174 - S174 .

Tahir S, Gillott H, Jackson-Spence F, Nath J, Mytton J, Evison F, Sharif A ( 2016 ) . BLACK KIDNEY ALLOGRAFT RECIPIENT OUTCOMES IN ENGLAND VS NEW YORK STATE: A COMPARATIVE POPULATION-COHORT ANALYSIS BETWEEN 2003 AND 2013 . NEPHROLOGY DIALYSIS TRANSPLANTATION . vol. 31 , 324 - 324 .

Tahir S, Jackson-Spence F, Gillott H, Everson F, Nath J, Sharif A ( 2016 ) . Black Ethnicity as a Risk Factor for Poor Kidney Allograft Outcomes Post-Transplantation . AMERICAN JOURNAL OF TRANSPLANTATION . vol. 16 , 259 - 259 .

Jackson-Spence F, Gillott H, Tahir S, Nath J, Mytton J, Evison F, Sharif A ( 2016 ) . CANCER INCIDENCE AND PROGRESSION TO MORTALITY AMONG KIDNEY ALLOGRAFT RECIPIENTS IN ENGLAND: A POPULATION-COHORT ANALYSIS BETWEEN 2003 AND 2013 . NEPHROLOGY DIALYSIS TRANSPLANTATION . vol. 31 , 310 - 310 .

Jackson-Spence F, Gillott H, Tahir S, Nath J, Mytton J, Evison F, Sharif A ( 2016 ) . CANCER-RELATED OUTCOMES IN KIDNEY ALLOGRAFT RECIPIENTS IN ENGLAND VERSUS NEW YORK STATE: A COMPARATIVE POPULATION-COHORT ANALYSIS BETWEEN 2003 AND 2013 . NEPHROLOGY DIALYSIS TRANSPLANTATION . vol. 31 , 316 - 317 .

Jackson-Spence F, Gillott H, Tahir S, Nath J, Evison F, Mytton J, Sharif A ( 2016 ) . Cancer-related incidence and progression to mortality among kidney allograft recipients in England: a population-cohort analysis between 2003 and 2013 . TRANSPLANTATION . vol. 100 , S261 - S261 .

Jackson-Spence F, Gillott H, Tahir S, Nath J, Evison F, Mytton J, Sharif A ( 2016 ) . Cancer-related outcomes in kidney allograft recipients in England versus New York State: a comparative population-cohort analysis between 2003 and 2013 . TRANSPLANTATION . vol. 100 , S174 - S174 .

Gillott H, Tahir S, Jackson-Spence F, Evison F, Nath J, Sharif A ( 2016 ) . DONOR SMOKING INCREASES KIDNEY ALLOGRAFT RECIPIENT MORTALITY IN A NATIONAL POPULATION COHORT ANALYSIS . NEPHROLOGY DIALYSIS TRANSPLANTATION . vol. 31 , 324 - 324 .

Gillott H, Jackson-Spence F, Tahir S, Evison F, Nath J, Sharif A ( 2016 ) . Donor Smoking Increases Kidney Allograft Recipient Mortality in a National Population Cohort Analysis . AMERICAN JOURNAL OF TRANSPLANTATION . vol. 16 , 532 - 532 .

Tahir S, Gillott H, Jackson-Spence F, Evison F, Nath J, Sharif A ( 2016 ) . OUTCOMES FOR KIDNEY ALLOGRAFT RECIPIENTS WITH LANGUAGE BARRIERS POST-TRANSPLANTATION - A COMPARATIVE ANALYSIS . NEPHROLOGY DIALYSIS TRANSPLANTATION . vol. 31 , 322 - 322 .

Tahir S, Jackson-Spence F, Gillott H, Everson F, Nath J, Sharif A ( 2016 ) . Outcomes for Kidney Allograft Recipients with Language Barriers Post-Transplantation - A Comparative Analysis . AMERICAN JOURNAL OF TRANSPLANTATION . vol. 16 , 496 - 496 .

Gillott H, Jackson-Spence F, Tahir S, Evison F, Nath J, Sharif A ( 2016 ) . SMOKING EXPOSURE AMONG KIDNEY ALLOGRAFT RECIPIENTS AND OUTCOMES AFTER TRANSPLANT . NEPHROLOGY DIALYSIS TRANSPLANTATION . vol. 31 , 1571 - 1571 .

Abbas S, Tahir S, Gillott H, Jackson-Spence F, Mytton J, Evison F, Nath J, Ferro CJ et al. ( 2016 ) . SOCIOECONOMIC DEPRIVATION AND OUTCOMES AFTER KIDNEY TRANSPLANTATION . NEPHROLOGY DIALYSIS TRANSPLANTATION . vol. 31 , 1581 - 1581 .

Gillott H, Tahir S, Jackson-Spence F, Evison F, Nath J, Sharif A ( 2016 ) . Smoking Exposure Among Kidney Allograft Recipients and Outcomes After Transplant . AMERICAN JOURNAL OF TRANSPLANTATION . vol. 16 , 325 - 325 .

Jackson-Spence F, Gillott H, Tahir S, Evison F, Nath J, Sharif A ( 2016 ) . Stratifying Skin Versus Non-Skin Cancer Risk Post-Kidney Transplantation According to Patient Characteristics . AMERICAN JOURNAL OF TRANSPLANTATION . vol. 16 , 780 - 780 .